Clinical Trial Update: A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

AstraZeneca is conducting a Phase 2 trial evaluating novel combinations for Non-Small Cell Lung Cancer, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING